JS25 is a selective covalent BTK inhibitor (IC50 = 5.8 nM) that inactivates BTK by chelating Tyr551; it inhibits cancer cell proliferation, induces cell death, shows efficacy in a Burkitt lymphoma xenograft mouse model, and is capable of crossing the blood-brain barrier.